SCHEMBL1766178

SCHEMBL1766178

COc1cc(N)cc(F)c1OC

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.44
HTR2C P28335 1/20 0.44
HTR2B P41595 1/20 0.44
CYP19A1 P11511 3/20 0.43
ACHE P22303 1/20 0.43
NQO2 P16083 1/20 0.43
MAPT P10636 3/20 0.41
CYP3A4 P08684 1/20 0.41
CA9 Q16790 1/20 0.41
GAA P10253 2/20 0.40
KDM4E B2RXH2 2/20 0.40
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39
HTT P42858 1/20 0.39
TUBB1 Q9H4B7 3/20 0.39
CYP1A2 P05177 1/20 0.39
PTGS2 P35354 1/20 0.39
POLB P06746 1/20 0.38
PTAFR P25105 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30682891 1.00 HTR2A (0.44) HTR2AHTR2CHTR2BCYP19A1ACHE
SCHEMBL3450618 0.86 PDGFRB (0.37) HTR2AHTR2CHTR2BCYP19A1ACHE
SCHEMBL191996 0.84 ACHE (0.59) HTR2AHTR2CHTR2BCYP19A1ACHE
Ammonia Solution, Strong SCHEMBL4946565 0.81 ACHE (0.56) HTR2AHTR2CHTR2BCYP19A1ACHE
Hydrochloric Acid SCHEMBL4381078 0.81 ACHE (0.56) HTR2AHTR2CHTR2BCYP19A1ACHE
SCHEMBL1119083 0.80 GAA (0.41) MAPTCYP3A4GAAKDM4ETSHR
SCHEMBL15492307 0.78 ALDH1A1 (0.35) HTR2AHTR2CHTR2BCYP19A1ACHE
SCHEMBL524923 0.78 MAPT (0.40) ACHEMAPTCYP3A4GAAKDM4E
SCHEMBL21264353 0.77 MAPT (0.47) HTR2AHTR2CHTR2BCYP19A1ACHE
SCHEMBL2529901 0.77 ACHE (0.46) HTR2AHTR2CHTR2BCYP19A1ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250361253-A1 STING AGONIST COMPOUNDS SUTRO BIOPHARMA INC (US) 2025-11-27 US disclosed
EP-4536672-A1 STING AGONIST COMPOUNDS Sutro Biopharma, Inc. (US) 2025-04-16 EP disclosed
WO-2023239675-A1 STING AGONIST COMPOUNDS SUTRO BIOPHARMA, INC. (US) 2023-12-14 WO disclosed
WO-2023239675-A1 STING AGONIST COMPOUNDS SUTRO BIOPHARMA, INC. (US) 2023-12-14 WO disclosed
US-20230263155-A1 5-(1H-INDOL-3-YL)-OXAZOLE, -OXADIAZOLE AND -FURAN DERIVATIVES AS ENHANCERS OF SPERM MOTILITY SPERMATECH AS (NO) 2023-08-24 US disclosed
EP-2763539-B1 ANTIBACTERIAL COMPOUNDS GLAXO GROUP LTD (GB) 2017-02-08 EP disclosed
EP-2763539-B1 ANTIBACTERIAL COMPOUNDS GLAXO GROUP LTD (GB) 2017-02-08 EP disclosed
US-9340556-B2 Antibacterial compounds GLAXO GROUP LIMITED (GB) 2016-05-17 US disclosed
US-9340556-B2 Antibacterial compounds GLAXO GROUP LIMITED (GB) 2016-05-17 US disclosed
CN-104039152-A Antibacterial compounds GLAXO GROUP LTD 2014-09-10 CN disclosed
US-20140249126-A1 ANTIBACTERIAL COMPOUNDS GLAXO GROUP LIMITED (GB) 2014-09-04 US disclosed
US-20140249126-A1 ANTIBACTERIAL COMPOUNDS GLAXO GROUP LIMITED (GB) 2014-09-04 US disclosed
EP-2763539-A1 ANTIBACTERIAL COMPOUNDS Glaxo Group Limited (GB) 2014-08-13 EP disclosed
WO-2013052568-A1 ANTIBACTERIAL COMPOUNDS GLAXO GROUP LIMITED (GB) 2013-04-11 WO disclosed
WO-2013052568-A1 ANTIBACTERIAL COMPOUNDS GLAXO GROUP LIMITED (GB) 2013-04-11 WO disclosed
US-20110104055-A1 SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES PROTEOTECH INC. 2011-05-05 US disclosed
US-20090060838-A1 SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES PROTEOTECH INC. 2009-03-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090060838-A1 SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES IAPP, SNCA, BACE2 HTR2A 219/4885HTR2C 394/4885HTR2B 375/4885
US-20230263155-A1 5-(1H-INDOL-3-YL)-OXAZOLE, -OXADIAZOLE AND -FURAN DERIVATIVES AS ENHANCERS OF SPERM MOTILITY NR5A1, NR1I3, NR5A2 HTR2A 502/4885HTR2C 296/4885HTR2B 198/4885
US-20140249126-A1 ANTIBACTERIAL COMPOUNDS MRPL21, PEPD, ABCB11 HTR2A 4612/4885HTR2C 4590/4885HTR2B 4445/4885
US-20110104055-A1 SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES IAPP, SNCA, BACE2 HTR2A 210/4885HTR2C 410/4885HTR2B 353/4885
US-20250361253-A1 STING AGONIST COMPOUNDS STING1, CGAS, MAVS HTR2A 1854/4885HTR2C 3073/4885HTR2B 2736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.